Please login to the form below

Not currently logged in
Email:
Password:

coeliac disease

This page shows the latest coeliac disease news and features for those working in and with pharma, biotech and healthcare.

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Deal includes upfront payment plus up to $330m in milestones. Takeda’s ‘build to buy’ strategy of partnering has resulted in a takeover deal for coeliac disease drug developer PvP Biologics. ... TAK-062 is a highly targeted therapy that could

Latest news

  • Almirall eyes $62m takeover of multicytokine specialist Bioniz Almirall eyes $62m takeover of multicytokine specialist Bioniz

    Bioniz' other candidates currently lie outside that focus. BNZ-2 is a subcutaneously-delivered IL-15 and IL-21 inhibitor with potential in coeliac disease and other inflammatory disorders of the

  • Genentech forges $800m autoimmune alliance with Parvus Genentech forges $800m autoimmune alliance with Parvus

    Genentech will work with Parvus to use its Navacim platform to develop candidates for inflammatory bowel disease, autoimmune liver diseases, and coeliac disease, and between Genentech and Novartis, all of Parvus’ ... One key characteristic of the

  • Human Cell Atlas gets new UK funding Human Cell Atlas gets new UK funding

    Creating a highly detailed atlas of the skin. A spotlight on immune-related diseases such as Inflammatory Bowel Disease and coeliac disease. ... She commented: “The Human Cell Atlas will transform our understanding of human health and disease, and we

  • FDA changes its mind on 23andMe's genetic testing kits FDA changes its mind on 23andMe's genetic testing kits

    Along with Alzheimer's and Parkinson's, the new Genetic Health Risk (GHR) test covers coeliac disease, alpha-1 antitrypsin deficiency, early onset primary dystonia, Factor XI deficiency, type 1 Gaucher ... tests. The exemption will not however include

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    Projects that address gut inflammation beyond IBD are focused on coeliac disease, acute pancreatitis and short bowel syndrome. ... The product is entering a phase 2 study. “Coeliac disease is well understood in Europe and has benefited from decades of

  • Deal Watch January 2017 Deal Watch January 2017

    It proved to be a very busy month for Takeda with the company paying $35m to PvP Biologics for KumaMax for coeliac disease which is in preclinical development. ... Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative

  • Pharma deals in May 2015 Pharma deals in May 2015

    Emanating from the initial co-development agreement signed with Selecta in 2012, Sanofi has exercised its option to an exclusive licence to develop an immunotherapy for the treatment of coeliac disease. ... 301. Selecta/ Sanofi. Exercise of option to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics